Although ASCT represents the unique potentially curative treatment for TP53-mutated AML/MDS patients, the risk of death after the procedure remains significantly high, with the majority of deaths mostly related to the occurrence of disease relapse. This evidence concerns the gene TP53 and acute myeloid leukemia.